Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea
- 1 February 2000
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (3) , 273-278
- https://doi.org/10.1097/00002030-200002180-00009
Abstract
Sensory neuropathy is a common adverse effect of the nucleoside analogue anti-retroviral drugs didanosine (ddI) and stauvudine (d4T). These drugs are increasingly being used in combination, and it is not currently known whether the incidence of neuropathy is higher with combination compared to individual drug use. It is also not known if hydroxyurea, used to potentiate the antiviral efficacy of these drugs, may also increase the risk of neuropathy. The purpose of this analysis is to investigate if the combination of ddI and d4T, with or without hydroxyurea, has a higher incidence of neuropathy than a single drug regimen. Data were obtained from patients followed longitudinally by the Johns Hopkins AIDS Services. Incidence rates of development of neuropathy were calculated for each of five regimens: ddI (± hydroxyurea), ddI + d4T (± hydroxyurea), and d4T. Cox proportional hazard regression was used to compare the relative risk of neuropathy for each regimen adjusting for CD4 cell count, other drugs received, and time on therapy. A total of 1116 patients received at least one of the five regimens. There were 117 cases of neuropathy. The crude incidence rate of neuropathy ranged from 6.8 cases per 100 person-years for ddI to 28.6 cases per 100 person-years for ddI + d4T + hydroxyurea. Compared with ddI alone, and adjusting for CD4 cell counts and other variables, the relative risk of neuropathy was 1.39 [95% confidence interval (CI): 0.84–2.32] for d4T alone, 2.35 (95% CI: 0.69–8.07) for ddI + hydroxurea, 3.50 (95% CI: 1.81–6.77) for ddI + d4T, and 7.80 (95% CI: 3.92–15.5) for ddI + d4T + hydroxyurea. Based on the data, the risk of neuropathy is additive or even synergistic for ddI + d4T + hydroxyurea compared with ddI or d4T alone. The combination of ddI + d4T also increases the risk of neuropathy but less than when hydroxyurea is included.Keywords
This publication has 11 references indexed in Scilit:
- Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathyNeurology, 1999
- Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patientsAIDS, 1998
- Peripheral Neuropathy with Nucleoside AntiretroviralsDrug Safety, 1998
- Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analoguesAIDS, 1997
- Low-dose zalcitabine-related toxic neuropathyNeurology, 1996
- Risk Factors for Dideoxynucleoside-Induced Toxic Neuropathy in Patients with the Human Immunodeficiency Virus InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- Hydroxyurea and AIDS: An Old Drug Finds a New Application?AIDS Research and Human Retroviruses, 1995
- Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 ReplicationScience, 1994
- Temporal trends in the incidence of HTV‐1‐related neurologic diseasesNeurology, 1994
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989